Cargando…
Patient preferences in Italy: health state utilities associated with attributes of weekly injection devices for treatment of type 2 diabetes
OBJECTIVES: Several glucagon-like peptide-1 receptor agonists are administered as weekly injections for treatment of type 2 diabetes (T2D). These medications vary in their injection processes, and a recent study in the UK found that these differences had an impact on patient preference and health st...
Autores principales: | Matza, Louis S, Boye, Kristina S, Jordan, Jessica B, Norrbacka, Kirsi, Gentilella, Raffaella, Tiebout, Amara R, Browne, Chantelle, Orsini Federici, Marco, Biricolti, Giovanni, Stewart, Katie D |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5995299/ https://www.ncbi.nlm.nih.gov/pubmed/29922043 http://dx.doi.org/10.2147/PPA.S159620 |
Ejemplares similares
-
Utilization Patterns of Glucagon-Like Peptide-1 Receptor Agonists in Patients with Type 2 Diabetes Mellitus in Italy: A Retrospective Cohort Study
por: Federici, Marco Orsini, et al.
Publicado: (2018) -
Patient Preferences and Health State Utilities Associated with Mealtime Insulin Concentrations Among Patients with Diabetes in Italy
por: Matza, Louis S., et al.
Publicado: (2019) -
Health state utilities associated with attributes of weekly injection devices for treatment of type 2 diabetes
por: Matza, Louis S., et al.
Publicado: (2017) -
The Real-World Observational Prospective Study of Health Outcomes with Dulaglutide and Liraglutide in Type 2 Diabetes Patients (TROPHIES): Design and Baseline Characteristics
por: García-Pérez, Luis-Emilio, et al.
Publicado: (2021) -
Health state utilities associated with treatment process for oral and injectable GLP-1 receptor agonists for type 2 diabetes
por: Matza, Louis S., et al.
Publicado: (2021)